Skip to main content

1-A CME | Slowing T1D Progression: Updates on Screening Tests and Emerging Treatments

This item is expired.

This 1-hour webinar will provide the latest updates on T1D autoantibody screening tests and programs, their role in identifying people who have a risk of developing T1D, best practices for monitoring and supporting patients following T1D autoantibody testing, and investigational therapies that may slow T1D progression in individuals with a high risk of developing T1D and those with new-onset T1D.

Upon completion, participants should be able to:

  • Recognize the different stages of T1D and the importance of preventing T1D diagnosis in diabetic ketoacidosis
  • Explain the benefits and limitations of T1D autoantibody screening tests to patients and families
  • Describe monitoring protocols and support resources for individuals who have tested positive for T1D autoantibodies
  • Identify therapies currently in clinical trials that may slow T1D progression in individuals with a high risk of developing T1D and in those with new onset T1D
This activity is available free of charge to participants.

If you have a question for the presenter following the video please send to elearning@acofp.org with the Unanswered Question: Slowing T1D Progression.

This activity was developed by Med-IQ in collaboration with ACOFP and JDRF.

This activity is supported by an educational grant from Provention Bio.

Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.

Jennifer McVean, MD
Consulting fees/advisory boards: Mannkind Corporation, Medtronic, Inc.
Fees received for promotional/non-CME activities: Medtronic, Inc.

Marian Rewers, MD, PhD
Consulting fees/advisory boards: F. Hoffmann-La Roche Ltd., Janssen Pharmaceuticals, Inc., Provention Bio, United Health Group
Contracted research: Janssen Pharmaceuticals, Inc.

Jay H. Shubrook, DO, FACOFP, FAAFP, BC-ADM
Consulting fees/advisory boards: Bayer HealthCare Pharmaceuticals, Eli Lilly and Company, Novo Nordisk

The American College of Osteopathic Family Physicians (ACOFP) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians. ACOFP designates this program for a maximum number of 1.0 AOA Category 1-A credits and will report CME with the extent of the physician’s participation in this activity.

This program is sponsored by ACOFP for educational purposes only. The material presented is not intended to represent the sole or best medical interventions for the discussed diagnoses, but rather is intended to present the opinions of the authors or presenters that may be helpful to other practitioners. Attendees participating in this medical education program do so with the full knowledge that they waive any claim they may have against ACOFP for reliance on any information presented during these educational activities.

© JDRF